Crescent Biopharma, Inc. (CBIO)
NCM · Healthcare · Biotechnology
$17.92
-2.29%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$494.1M
Shares Outstanding
27.6M
P/S (TTM)
41.6x
Exchange
NCM
Currency
USD
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 10.8M | 1.0M |
| Operating Income | -21.0M | -25.9M | -91.5M | -24.7M |
| Net Income | -21.8M | -24.6M | -92.4M | -23.3M |
| Diluted EPS | $-4.93 | $-1.27 | $-4.01 | $-0.70 |
Annual Financials
| Metric | 2025-12-31 |
|---|---|
| Revenue | 10.8M |
| Operating Income | -152.6M |
| Net Income | -153.9M |
| Diluted EPS | $-12.81 |